Letters sent to healthcare professionals in April 2018

Letters were sent about insulin Fiasp and Tresiba and Inhixa (enoxaparin sodium); use survey to feedback your thoughts on Direct Healthcare Professional Communications (DHPCs) and on the way medicines safety issues are communicated.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 24 May 2018

• Therapeutic area: Cardiovascular disease and lipidology, Endocrinology, diabetology and metabolism, Haematology and Neurology

In April 2018, letters were sent to healthcare professionals about:

• Risk of mix-ups between insulin Fiasp (fast-acting insulin aspart) and Tresiba (basal insulin degludec)

• Inhixa (enoxaparin sodium) solution for injection: rare cases of self-activation of safety device in unopened, unused pre-filled syringes

Finally, complete this 10-minute survey to tell us your views on the way medicines safety issues are communicated and how we might improve this to better support safe and effective use.

Article citation: Drug Safety Update volume 11 issue 10; May 2018: 3.

Published 24 May 2018